IRIS
MORGILLO, Floriana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.223
NA - Nord America 5.496
AS - Asia 4.898
SA - Sud America 678
AF - Africa 66
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 6
Totale 23.380
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 7.903
US - Stati Uniti d'America 5.394
SG - Singapore 1.600
IE - Irlanda 1.196
CN - Cina 1.063
IT - Italia 920
HK - Hong Kong 808
VN - Vietnam 616
BR - Brasile 583
DE - Germania 467
GB - Regno Unito 449
UA - Ucraina 403
FR - Francia 293
KR - Corea 253
FI - Finlandia 157
SE - Svezia 143
IN - India 136
TR - Turchia 135
GR - Grecia 98
JP - Giappone 91
CA - Canada 55
NL - Olanda 39
AR - Argentina 38
AT - Austria 38
PK - Pakistan 37
BD - Bangladesh 34
MX - Messico 28
BE - Belgio 24
ID - Indonesia 20
IQ - Iraq 17
PL - Polonia 17
ES - Italia 15
ZA - Sudafrica 14
EC - Ecuador 13
CL - Cile 12
PH - Filippine 11
CH - Svizzera 10
CO - Colombia 10
CZ - Repubblica Ceca 10
KE - Kenya 9
AE - Emirati Arabi Uniti 8
AU - Australia 7
HU - Ungheria 7
IR - Iran 7
MA - Marocco 7
SA - Arabia Saudita 7
TN - Tunisia 7
TW - Taiwan 7
UZ - Uzbekistan 7
VE - Venezuela 7
EG - Egitto 6
NZ - Nuova Zelanda 6
PY - Paraguay 6
AO - Angola 5
AZ - Azerbaigian 5
DZ - Algeria 5
EU - Europa 5
IL - Israele 5
LT - Lituania 5
AL - Albania 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
JO - Giordania 4
MK - Macedonia 4
NP - Nepal 4
OM - Oman 4
PE - Perù 4
TH - Thailandia 4
KZ - Kazakistan 3
MY - Malesia 3
RO - Romania 3
SN - Senegal 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
BO - Bolivia 2
CG - Congo 2
GA - Gabon 2
HN - Honduras 2
HR - Croazia 2
JM - Giamaica 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
PA - Panama 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
IS - Islanda 1
KG - Kirghizistan 1
KW - Kuwait 1
ML - Mali 1
MU - Mauritius 1
NG - Nigeria 1
Totale 23.372
Salva come PNG Salva come JPEG
Città #
Moscow 2.854
Dublin 1.188
Hong Kong 794
Singapore 706
San Jose 674
Chandler 662
Jacksonville 631
Santa Clara 629
Ashburn 249
Seoul 231
Ho Chi Minh City 194
Naples 183
Beijing 182
Princeton 164
Bremen 162
New York 145
Hanoi 139
Medford 129
Ann Arbor 128
Hefei 125
Roxbury 125
Dallas 121
Caserta 119
Munich 106
Wilmington 87
Bengaluru 86
Los Angeles 80
The Dalles 79
São Paulo 62
Boardman 59
Nanjing 56
San Mateo 46
Woodbridge 45
Cambridge 44
Haiphong 39
Da Nang 38
Turku 38
Des Moines 37
Napoli 34
Council Bluffs 29
Milan 29
Nuremberg 29
Elora 28
Amsterdam 25
Houston 25
Brussels 24
Dong Ket 24
Rio de Janeiro 23
Jinan 22
Vienna 21
Orem 20
Rome 20
Helsinki 18
Mountain View 18
Tianjin 17
Nanchang 16
Atlanta 15
Brasília 15
Brooklyn 15
Istanbul 15
Aiello Del Sabato 14
London 14
Shanghai 14
Chicago 13
Düsseldorf 13
Frankfurt am Main 13
Tokyo 13
Warsaw 13
Afragola 12
Belo Horizonte 12
Curitiba 12
Norwalk 12
Aversa 11
Ercolano 11
Hải Dương 11
Mumbai 11
Ninh Bình 11
Zhengzhou 11
Guarulhos 10
Lappeenranta 10
Auburn Hills 9
Boston 9
Brno 9
Falkenstein 9
Hangzhou 9
Thái Bình 9
Bahawalpur 8
Chennai 8
Columbus 8
Guangzhou 8
Jakarta 8
Nairobi 8
Shenyang 8
Thái Nguyên 8
Toronto 8
Biên Hòa 7
Bến Tre 7
Can Tho 7
Cava Dei Tirreni 7
City of London 7
Totale 12.320
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 244
ONCOLOGIA MEDICA 206
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 204
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 201
AXL is an oncotarget in human colorectal cancer 194
Adequacy of Cytologic Samples by Ultrasound-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology of Peripheral Pulmonary Nodules for Morphologic Diagnosis and Molecular Evaluations: Comparison With Computed Tomography-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology 193
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 190
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 183
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 182
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 181
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 179
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 177
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 177
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 173
Immunotherapy for head and neck cancer: Present and future 171
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 170
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 170
Chronic inflammation and oxidative stress in human carcinogenesis 169
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 165
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 164
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 163
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 161
Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies 160
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 159
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 159
A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS-The Experience in Pathological Anatomy Unit 158
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 157
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 157
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 157
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 156
Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold! 155
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 154
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 154
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 150
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 150
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 149
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 149
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 148
Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication(dagger) 148
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 146
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 146
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 146
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 145
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 145
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 144
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 144
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 143
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 140
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 139
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 138
Farmacogenomica e cancro colorettale 137
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 137
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 137
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 136
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 136
PercuTwist tracheostomy in an intubated patient with tracheal stent 136
Discovery of N-Substituted-2-Oxoindolin Benzoylhydrazines as c-MET/SMO Modulators in EGFRi-Resistant Non-Small Cell Lung Cancer 135
The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. 135
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 134
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond 134
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 133
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 133
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. 130
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 130
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 130
Vedolizumab as Rescue Therapy in Carboplatin-Gemcitabine-Induced Triggered Acute Severe Ulcerative Colitis Flare-Up 129
Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival 129
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 128
TRASTUZUMAB RESISTANCE IN BREAST CANCER 128
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 127
Pimasertib hydrochloride 127
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 126
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 126
First-Line Erlotinib Followed by Second-Line Cisplatin- Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial 125
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 125
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 124
Serum vascular endothelial growth factor (VEGF)levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 124
AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma 124
Targeting EGFR in Pancreatic Cancer Treatment. 123
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 123
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 123
PET-TC BODY CON FDG IN ONCOLOGIA 121
Trimodality treatment in early-stage malignant pleural mesothelioma. Preliminary results of a multicenter phase II trial 121
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 121
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials 120
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 120
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 119
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 117
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 116
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 116
Rescue Surgery for Advanced Stage Lung Cancer: A Systematic Review 115
Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. 115
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 115
Preoperative chemo-radiotherapy for carcinoma of the esophagus 114
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 114
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 114
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems 113
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib 113
It is finally time for adjuvant therapy in melanoma 113
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 113
Totale 14.447
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.048
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.048
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021322 0 0 0 0 0 0 0 0 0 133 126 63
2021/20221.185 56 17 24 28 374 17 45 45 49 101 107 322
2022/20232.502 253 65 39 245 311 203 11 146 1.115 19 49 46
2023/2024935 82 34 43 55 291 132 18 26 16 18 74 146
2024/20253.049 33 62 30 77 453 402 397 261 438 412 260 224
2025/202613.071 516 605 653 619 1.053 7.361 781 733 487 263 0 0
Totale 23.865